Novo Nordisk has repurchased 18,325,000 B shares for a total transaction value of DKK 5,526,186,488 under the share repurchase programme it initiated on 6 May 2026. That programme, running from 6 May 2026 to 1 February 2027, allows repurchases of up to DKK 11,200,000,010.45 and is itself part of the company's overall share repurchase programme of up to DKK 15 billion to be executed over the 12-month period beginning 4 February 2026. In the latest week, Novo Nordisk bought 210,000 B shares on each of 7, 8, 9, 10 and 11 September 2026, at average purchase prices of 297.98, 295.53, 289.37, 288.08 and 278.62 Danish kroner respectively. With these transactions, Novo Nordisk holds 47,124,876 B shares as treasury shares, equal to 1.1% of its share capital, out of a total of 4,465,000,000 A and B shares including treasury shares. Since 4 February 2026, the company has repurchased a total of 33,084,179 B shares at an average price of DKK 281.89 per B share, a transaction value of DKK 9,326,186,478.
Novo Nordisk A/SNovo Nordisk is executing its DKK 11.2bn share repurchase tranche, buying back 18.3 million B shares.
